RISA Labs has raised $11.1 million in Series A funding to scale its AI-powered operating system for oncology care, marking a significant step in modernising cancer treatment workflows. Founded in 2024 by Kshitij Jaggi and Kumar Shivang, the healthtech startup is expanding its BOSS Console across US cancer clinics, pharmacies, and infusion networks, aiming to streamline complex care pathways and accelerate patient access to therapies.Backed by Cencora and Optum Ventures, RISA Labs addresses the growing complexity of oncology care, where thousands of potential treatment paths exist for each patient. CEO Kshitij Jaggi highlights the dual mission: enabling patients to reach the right therapy faster while using data to improve outcomes for future patients. CTO Kumar Shivang describes BOSS Console as a low-entropy thinking information machine—an intelligent companion that absorbs clinical complexity, reduces administrative burdens, and supports informed decision-making.
Senior VP Jason Dinger of Cencora emphasises the importance of such solutions as oncology treatments multiply in number and complexity, making streamlined operations and efficient therapy access vital. The funding will support RISA Labs in scaling its technology, expanding adoption, and deepening its impact on oncology care delivery.
By combining AI intelligence with operational precision, RISA Labs is redefining how cancer care is managed—ensuring clinicians can focus on patient outcomes while navigating the intricacies of modern oncology. The Series A marks a pivotal phase for the startup as it builds a data-driven, scalable platform that promises faster, smarter, and more efficient cancer care.
